11 Biggest Generic Drug Companies in the World
When it comes to 11 Biggest Generic Drug Companies in the World one can say that the list hasn’t changed a great deal over the years.
Posts Tagged ‘NYSE:SNY’
For Sanofi SA (ADR) (SNY) Chronic Diseases Present the Future Focus
In an interview with CNBC, Chris Viehbacher, the CEO of Sanofi SA (ADR) (NYSE:SNY), discussed the steps that big pharma companies like Sanofi SA (ADR) (NYSE:SNY) are taking to...
Sanofi-Aventis Purchases $42.4 Million Worth of Regeneron Pharmaceuticals Inc (REGN)’s Stock
On Jan. 29th, Sanofi-Aventis, a European pharmaceutical group and Large Shareholder at Regeneron Pharmaceuticals Inc (NASDAQ:REGN), filed a Form 4 report at the U.S.
Abrams Capital Management Trims the Stake in Engility Holdings Inc (EGL)
Abrams Capital Management, led by David Abrams significantly trimmed its stake in Engility Holdings Inc (NYSE:EGL).
Everything You Need to Know About the Upcoming Flu Season
To me, flu season is a lot like Christmas; there's a defined time period when we expect it to occur, yet it seems to appear earlier and earlier every year.
Four Reasons to Buy This Biotechnology Stock
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), a developer and marketer of RNA-based novel drugs to treat a variety of diseases, has been one of the best performing stocks in the ...
Sanofi SA (ADR) (SNY), Biodel Inc (BIOD): Would It Be Foolish to Trust Unilife Corp (UNIS)?
Shares of drug delivery systems manufacturer Unilife Corp (NASDAQ:UNIS) recently rallied after it announced a long-term contract to sell prefilled syringes to pharma giant Sanofi...
Sanofi SA (ADR) (SNY), Roche Holding Ltd. (ADR) (RHHBY), GlaxoSmithKline plc (ADR) (GSK): Is the Tide About to Turn in the Fight Against Chronic Lymphocytic Leukemia?
There is perhaps nothing scarier than a cancer diagnosis.
Regeneron Pharmaceuticals Inc (REGN): Should You Follow in Sanofi SA (ADR) (SNY)’s Footsteps and Invest in This Booming Biotech?
More than anything, biotech companies need investors who are true believers in their products.
Sanofi SA (ADR) (SNY), Regeneron Pharmaceuticals Inc (REGN): Getting Closer
French drugmaker Sanofi SA (ADR) (NYSE:SNY) counted that much money in its coffers as of the end of June, including cash, cash equivalents, and short-term investments.
Sanofi SA (ADR) (SNY), Shire PLC (ADR) (SHPG): Making Sense of the Drama About Viropharma Inc (VPHM)
In the world of small biotech companies, investors are always fishing for the next small fish to be gobbled up by a bigger one since the industry is well-known for its hefty acquisition...
Regeneron Pharmaceuticals Inc (REGN), Viropharma Inc (VPHM): Sanofi SA (ADR) (SNY)’s Interest Sparks Biotech Stocks in a Huge Week for Investors
Looking for the best-performing sector in this year's big market rally? It may just be the biotech sector, which has erupted with astronomical gains in 2013.
Amgen, Inc. (AMGN), Impax Laboratories Inc (IPXL): Keryx Biopharmaceuticals (KERX)’s Stifel Conference Presentation
There were definitely some good parts in what Keryx Biopharmaceuticals (NASDAQ:KERX) had to say at this week's Stifel Nicolaus Weisel Healthcare Conference in Boston.
GameStop Corp. (GME), Safeway Inc. (SWY), Regeneron Pharmaceuticals Inc (REGN): Friday’s Three Best Stocks
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Apple Inc. (AAPL), NIKE, Inc. (NKE): The Mobile Future of Diabetes Treatments
In my opinion, the Nike+ FuelBand released by Apple Inc. (NASDAQ:AAPL) and NIKE, Inc. (NYSE:NKE) last year was a seminal product in health care tech.
Sanofi SA (ADR) (SNY), Biodel Inc (BIOD): When Will Unilife Corp (UNIS) Earnings Go Positive?
Unilife Corp (NASDAQ:UNIS) will release its quarterly report on Tuesday, but investors already have reason to believe that the company won't make a profit.
Sanofi SA (ADR) (SNY), Bristol Myers Squibb Co. (BMY): Why Peregrine Pharmaceuticals (PPHM) Earnings Won’t Show Profits
Peregrine Pharmaceuticals (NASDAQ:PPHM) will release its latest quarterly report on Monday, and investors are under no illusions that the company will avoid losing money again...
This Metric Says You Are Smart to Buy GlaxoSmithKline plc (ADR) (GSK)
In the financial world, there are many methods market participants can use to track the equity markets.
Biogen Idec Inc. (BIIB), Incyte Corporation (INCY): Should Novartis AG (ADR) (NVS) Shareholders Be Worried About This?
As an investor in the health care sector, it can sometimes feel like everything -- and everyone -- is out to get you.
Allergan, Inc. (AGN), Sanofi SA (ADR) (SNY): New FDA Guidelines Hit This Company Hard
Allergan, Inc. (NYSE:AGN), the diversified health care giant best known for Botox, boasts an impressive portfolio of products.
Pfizer Inc. (PFE), Zoetis Inc (ZTS), Merck & Co., Inc. (MRK), Sanofi SA (ADR) (SNY): 5 Reasons to Invest in Animal Health
In an attempt to further simplify its business and unlock shareholder value, Pfizer Inc. (NYSE:PFE) has been busy divesting itself of non-core assets.
Hedge Funds Are Buying Novartis AG (ADR) (NVS)
In the 21st century investor’s toolkit, there are dozens of methods market participants can use to monitor the equity markets.
Eli Lilly & Co. (LLY), Merck & Co., Inc. (MRK), Sanofi SA (ADR) (SNY): Positive News for This Troubled Pharma Player
Eli Lilly & Co. (NYSE:LLY) recently rose nearly 3% following positive phase 3 results for cancer drug necitumumab.
Peregrine Pharmaceuticals (PPHM), Sanofi SA (ADR) (SNY): Is This Experimental Lung Cancer Drug Back on Track?
Peregrine Pharmaceuticals (NASDAQ:PPHM), a developmental stage biotech focusing on oncology treatments, recently announced that its lead drug candidate, bavituximab, was heading...
Is Sanofi SA (ADR) (SNY) Going to Burn These Hedge Funds?
To the average investor, there are plenty of gauges investors can use to track Mr. Market. Some of the most useful are hedge fund and insider trading interest.
Someone’s Selling Pfizer Inc. (PFE) Shares, Should You?
Now, according to many traders, hedge funds are seen as delayed, outdated investment tools of an era lost to time.
Pfizer Inc. (PFE), Regeneron Pharmaceuticals Inc (REGN): Are These Drugs the Future of High-Cholesterol Treatment?
Once upon a time in a regulatory environment far, far away, there was a cholesterol-fighting drug named Lipitor from Pfizer Inc. (NYSE:PFE).
Biogen Idec Inc. (BIIB), Teva Pharmaceutical Industries Ltd (ADR) (TEVA), Novartis AG (ADR) (NVS): Companies Leading the Fight Against Multiple Sclerosis
It's a disease that doesn't often find itself in the spotlight, but multiple sclerosis is quickly becoming an ailment that drugmakers are focusing their efforts on to make a quality...
Regeneron Pharmaceuticals Inc (REGN), Sanofi SA (ADR) (SNY): This Pharma Stock Is Ready to Reach New Heights
Earlier this year, in May, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) was soaring on news of FDA approval of the Eylea injection.
Sanofi SA (ADR) (SNY), Merck & Co., Inc. (MRK): Healthier Days Loom as 3 Big Pharmas Move on Dengue Shots
Mosquito bites sure suck, literally and figuratively. But more so if these are delivered by the insects’ female species, which cause viral infections. But forget malaria.
Dendreon Corporation (DNDN), Merrimack Pharmaceuticals Inc (MACK), Novavax, Inc. (NVAX): Three Horrendous Health-Care Stocks This Week
August might be hot for most of the country, but the first full week of the month wasn't so hot for some stocks.
GlaxoSmithKline plc (ADR) (GSK), Merck & Co., Inc. (MRK): The 10 Most Common Reasons People Visit Their Doctor
With the full implementation of the individual portion of the Patient Protection and Affordable Care Act less than five months away, physicians and doctor's offices around the...
Regeneron Pharmaceuticals Inc (REGN), Sanofi SA (ADR) (SNY): Is This Biotech Slowing?
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) closed Tuesday down over 6% following a second quarter report that missed estimates.
Sanofi SA (ADR) (SNY), GlaxoSmithKline plc (ADR) (GSK): This Company Is Tackling Multiple Sclerosis Head On
Currently existing immunomodulatory drugs that treat Multiple Sclerosis only work to treat relapse or attacks, manage symptoms, or modify the course of the disease.
Aegerion Pharmaceuticals, Inc. (AEGR), ISIS Pharmaceuticals, Inc. (ISIS), Sanofi SA (ADR) (SNY): This Is One Incredible CEO
The Motley Fool's readers have spoken, and I have heeded their cries.
Questcor Pharmaceuticals Inc (QCOR), ISIS Pharmaceuticals, Inc. (ISIS): Despite a Mid-Stage Disappointment, This Biotech Stock Is Still in Great Shape
As human beings it can sometimes be difficult for us to see the good in a bad situation.
Pfizer Inc. (PFE), Amgen, Inc. (AMGN): The Best-Selling Medications of 2013 (So Far)
Believe it or not, 2013 is getting close to being two-thirds of the way over. Many pharmaceutical firms have enjoyed great stock returns and nice profits thus far in the year.
Pfizer Inc. (PFE), Merck & Co., Inc. (MRK): Will Zoetis Earnings Deliver on Post-Spinoff Growth?
Zoetis will release its quarterly report on Tuesday, and investors will get their first look at the company as a completely independent business entity.
Array Biopharma Inc (ARRY), Sanofi SA (ADR) (SNY), Regeneron Pharmaceuticals Inc (REGN): Three Ways Your Kids Can Be Harmed by Smog
Around four in 10 Americans live in places where smog can impact their health.
Will Regeneron Pharmaceuticals Inc (REGN) Earnings Grow Fast Enough for Investors?
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) will release its quarterly report on Tuesday, and the company's stock has been on an absolute tear over the past year.
Three Things You Need to Know From Keryx Biopharmaceuticals (KERX)’s Q2 Earnings
Keryx Biopharmaceuticals (NASDAQ:KERX) announced its second-quarter results before the market opened on Thursday.
Novo Nordisk A/S (ADR) (NVO): Three Shocking Numbers on Diabetes’ Grim Future
Diabetes is one of the world's most dangerous and fastest-growing afflictions.
Biogen Idec Inc (BIIB), Pfizer Inc. (PFE): Out With the Old, In With the New in Treating MS
Hidden beneath all the numbers and metrics in Biogen Idec Inc (NASDAQ:BIIB)'s recent earnings report is a key confirmation of a shifting market in the treatment of multiple sclerosis...
Sanofi SA (ADR) (SNY), Vanda Pharmaceuticals Inc. (VNDA), Merck & Co., Inc. (MRK) – Sleep War Z: A Written History of the Insomniac War
It’s estimated that 30% to 40% of adults in the world experience some degree of insomnia every year. Most of these cases aren’t chronic and do not require medication.
Things You Need to Know From Questcor Pharmaceuticals Inc (QCOR)’s Killer Q2 Earnings
Three months ago after Questcor Pharmaceuticals Inc (NASDAQ:QCOR) announced its first-quarter financial results, I asked if those results were as bad as they looked.
The Procter & Gamble Company (PG), Merck & Co., Inc. (MRK): The Six Biggest Risk Factors for Insomnia
We often take sleep, the number of hours we get to sleep, or the quality of sleep we get, for granted.
Celgene Corporation (CELG): Has Multiple Myeloma Met its Match?
Multiple myeloma is a cancer of plasma cells, a type of white blood cell present in bone marrow.
Four Potential Suitors for Onyx Pharmaceuticals, Inc. (ONXX)
The "people familiar with the matter" are out in full force spouting off about who's bidding for Onyx Pharmaceuticals, Inc.
Merck & Co., Inc. (MRK)’s Late-Stage Breakdown
The Food and Drug Administration cancelled an advisory meeting planned for Merck & Co., Inc. (NYSE:MRK)’s post-surgery drug sugammadex.
The Future of Sanofi SA (ADR) (SNY)’s Insulin Empire
Sanofi SA (ADR) (NYSE:SNY) appeared at the American Diabetes Association meeting last month, touting data for the new insulin U300 and a combo therapy involving its approved drugs...
